We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-17.8%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$4.58B
AUM Growth
-$1.09B
Cap. Flow
+$290M
Cap. Flow %
6.34%
Top 10 Hldgs %
44.83%
Holding
107
New
10
Increased
11
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$158M
2
NTRA icon
Natera
NTRA
+$78.7M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$62.7M
4
ANTX icon
AN2 Therapeutics
ANTX
+$55.6M
5
CTKB icon
Cytek Biosciences
CTKB
+$51M

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$125M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$61.3M
3
ZGNX
Zogenix, Inc.
ZGNX
+$54.2M
4
CCCC icon
C4 Therapeutics
CCCC
+$44.4M
5
TGTX icon
TG Therapeutics
TGTX
+$42M

Sector Composition

Rank Sector Weight
1 Healthcare 97.97%
2 Financials 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.6B
$888M 19.38%
7,567,900
– –
BIIB icon
2
Biogen
BIIB
$30.6B
$153M 3.34%
+727,024
New +$158M
JBIO
3
Jade Biosciences
JBIO
$1.21B
$151M 3.31%
236,114
– –
CTKB icon
4
Cytek Biosciences
CTKB
$566M
$144M 3.15%
13,381,054
+3,774,026
+39% +$51M
ITOS
5
DELISTED
iTeos Therapeutics
ITOS
$142M 3.1%
4,417,259
– –
TVTX icon
6
Travere Therapeutics
TVTX
$5.29B
$127M 2.77%
4,922,941
-691,487
-12% -$18.4M
JANX icon
7
Janux Therapeutics
JANX
$922M
$124M 2.71%
8,670,644
– –
PCVX icon
8
Vaxcyte
PCVX
$7.71B
$111M 2.41%
4,581,203
+340,739
+8% +$7.44M
CLYM
9
Climb Bio
CLYM
$708M
$110M 2.41%
13,150,849
– –
IMGN
10
DELISTED
Immunogen Inc
IMGN
$103M 2.26%
21,741,458
+1,500,000
+7% +$8.3M
DICE
11
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$99.6M 2.17%
5,208,911
– –
GHRS icon
12
GH Research
GHRS
$1.94B
$88.3M 1.93%
4,827,330
+1,983,573
+70% +$35M
FMTX
13
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$83.8M 1.83%
9,011,651
– –
TYRA icon
14
Tyra Biosciences
TYRA
$1.87B
$77.4M 1.69%
7,236,454
– –
PNT
15
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$71.8M 1.57%
9,003,018
– –
CLDX icon
16
Celldex Therapeutics
CLDX
$2.92B
$70.7M 1.54%
2,075,000
+270,205
+15% +$8.64M
BLU
17
DELISTED
BELLUS Health Inc.
BLU
$70.4M 1.54%
10,230,274
– –
ENTA icon
18
Enanta Pharmaceuticals
ENTA
$369M
$68.6M 1.5%
+964,212
New +$62.7M
VOR icon
19
Vor Biopharma
VOR
$1.08B
$67.2M 1.47%
556,049
– –
NKTX icon
20
Nkarta
NKTX
$153M
$63.8M 1.39%
5,605,129
– –
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$60.4M 1.32%
734,343
+353,297
+93% +$36.1M
DAWN
22
DELISTED
Day One Biopharmaceuticals
DAWN
$60.1M 1.31%
6,060,090
+1,094,502
+22% +$14.5M
RYTM icon
23
Rhythm Pharmaceuticals
RYTM
$7.4B
$56.1M 1.22%
4,871,067
– –
ANTX icon
24
AN2 Therapeutics
ANTX
$179M
$55.3M 1.21%
+3,666,663
New +$55.6M
RLMD icon
25
Relmada Therapeutics
RLMD
$551M
$54M 1.18%
2,000,000
– –
1
2 3 4 5

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, RA Capital Management held 107 positions worth $4.58B, down 19% from $5.67B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management deployed $290M of net new capital in Q1 2022, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was Biogen: 727,024 shares worth $153M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Novavax, an estimated $125M trimmed.

  • RA Capital Management's largest Q1 2022 buy was Biogen: 727,024 shares worth $153M.
  • RA Capital Management added most to Cytek Biosciences in Q1 2022, an estimated $51M increase.
  • RA Capital Management's biggest Q1 2022 reduction was Novavax, cutting an estimated $125M.
  • RA Capital Management fully exited Phathom Pharmaceuticals in Q1 2022, selling an estimated $61.3M.
  • RA Capital Management's ten largest holdings make up 45% of its $4.58B portfolio in Q1 2022.
  • RA Capital Management opened 10 new positions and closed 11 in Q1 2022.
  • RA Capital Management's portfolio value fell 19% quarter-over-quarter to $4.58B.

Based on RA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.